Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenic Purpura

Trial Profile

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenic Purpura

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRN 1008 (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 10 Dec 2019 Results (n=21; as of 15 July 2019) assessing presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Dec 2019 According to an Principia Biopharma media release, the company will hold an investor event to review the ITP data presented at ASH and the ITP landscape. The event will be available via live webcast.
    • 07 Dec 2019 According to an Principia Biopharma media release, a complete analysis of this trial will be presented at an upcoming medical conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top